Delivery University
Resume:
CURRICULUM VITAE
Tamara Minko, Ph. D.
Professor and Chair
Department of Pharmaceutics Office: 732-***-**** x 214
Ernest Mario School of Pharmacy Mobile: 732-***-****
Rutgers, The State University of New Jersey Fax: 732-***-****
160 Frelinghuysen Road Email: abqbsb@r.postjobfree.com
Piscataway, NJ 08854-8020 http://ceutics.rutgers.edu/minkohome.shtml
Editor, Pharmaceutical Research http://www.pharmres.org
Personal:
Citizenship: United States
Marital status: Married, one son
Professional Profile:
Tamara Minko is a Professor and Chair of the Department of Pharmaceutics at Ernest Mario
School of Pharmacy at Rutgers, the State University of New Jersey. She is a Fellow of the
American Association of Pharmaceutical Scientists, member of Board of Scientific Advisors of
the Controlled Release Society, an Editor of Pharmaceutical Research and member of the
editorial boards of four scientific journals. Dr. Minko serves as a reviewer for the National
Institutes of Health, Department of Defense, and the American Heart Association Scientific
Review Panels. She is an author and co-author of more than 350 publications (104 published and
accepted peer-reviewed papers, 17 books and textbook chapters, more than 250 conference
proceedings/abstracts and few patent applications). Dr. Minko's research has been supported by
grants from the National Institutes of Health, National Science Foundation, American Lung
Association, Department of Defense and several other national and international sources.
Appointments, Affiliations and Experience:
Chair, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State
University of New Jersey, Piscataway, New Jersey, 2008 Present
Acting Director, The Graduate Program in Pharmaceutical Science, Rutgers, The State
University of New Jersey, 2008
Professor, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The
State University of New Jersey, Piscataway, New Jersey, 2007 Present
Associate Professor, Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers, The State University of New Jersey, Piscataway, New Jersey, 2003-2007
Member, Cancer Institute of New Jersey, New Brunswick, NJ, 2001-Present
Member, Environmental and Occupational Health Science Institute (EOSHI), Piscataway,
NJ, 2001-Present
Member, New Jersey Center for Biomaterials, Piscataway, New Jersey, 2001-Present
Tamara Minko
Member, Graduate Program in Pharmaceutical Science, Rutgers, The State University of
New Jersey, Piscataway, New Jersey, 2000-Present
Assistant Professor, Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers, The State University of New Jersey, Piscataway, New Jersey, 2000-2003
Research Assistant Professor, Department of Pharmaceutics and Pharmaceutical Chemistry,
College of Pharmacy, University of Utah, Salt Lake City, Utah, 1999-2000
Research Associate, Department of Pharmaceutics and Pharmaceutical Chemistry, College of
Pharmacy, University of Utah, Salt Lake City, Utah, 1997-1998
Senior Research Specialist, Department of Cardiovascular Genetics, College of Medicine,
University of Utah, Salt Lake City, Utah, 1994-1996
Senior Scientific Officer (corresponding to the Associate Professor in the USA), Institute of
Physiology, Ukrainian Academy of Sciences, Kiev, Ukraine, 1988-1993
Scientific Officer (corresponding to the Assistant Professor in the USA), Institute of
Physiology, Ukrainian Academy of Sciences, Kiev, Ukraine, 1986-1988
Junior Scientific Officer, Institute of Physiology, Ukrainian Academy of Sciences, Kiev,
Ukraine, 1984-1986
Ph.D. Graduate Student, Institute of Physiology, Ukrainian Academy of Sciences, Kiev,
Ukraine 1980-1984
Lecturer, College of Nursing, Kiev, Ukraine 1977-1980
Education:
Postdoctoral Training, Pharmaceutics and Pharmaceutical Chemistry, Department of
Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt
Lake City, Utah, 1997-1998 (Advisor Jindrich Kopecek, Ph.D., D.Sc., Professor and Chair).
Postdoctoral Training, Cellular and Molecular Biology, Department of Cardiovascular Genetics,
School of Medicine, University of Utah, Salt Lake City, Utah, 1994-1996 (Advisor Roger
Williams, M.D., Professor and Chair).
Ph.D., Physiology (Cellular and Molecular), Institute of Physiology Ukrainian Academy of
Sciences, Ukraine, 1984 (Advisor Asya Z. Kolchinskaya, M.D., Ph.D., D.Sc., Professor and
Chair).
M.S., Biochemistry (honor), Mordovsky State University, Russia, 1977 (Advisor Nonna V.
Alba, Ph.D., Professor).
Current Research Interests:
Biopharmaceutics; targeted drug delivery; nanotechnology (polymers, dendrimers, liposomes,
etc.) for cancer detection and treatment; molecular targeting; non-viral nanoscale-based delivery
of antisense oligonucleotides, siRNA and peptides; mechanisms of multidrug resistance;
intracellular fate and molecular mechanisms of action of anticancer drugs: apoptosis and
2
Tamara Minko
necrosis, signal transduction, antiapoptotic cellular defensive mechanisms; use of
macromolecules for drug delivery; preclinical evaluation of anticancer drugs; tumor hypoxia;
modulation of cell death mechanisms during hypoxia.
Research Support:
Ongoing
1. 09/01/10 08/31/15. NIH/NCI R01CA138533, T. Minko - Principal Investigator.
Multifunctional Nanotherapeutics for Cancer Treatment and Imaging. Total $1,545,018
(Direct $1,000,000; Indirect $545,018).
2. 08/01/09 07/31/11. NIH/NCI (ARRA) R01 CA100098, T. Minko Principal Investigator,
Targeted Proapoptotic Anticancer Drug Delivery System. Total $862,285 (Direct
$645,958; Indirect $216,327).
3. 04/07/06 02/28/11. NIH/NCI R01 CA111766, T. Minko Principal Investigator.
Molecular targeting of drug delivery system to cancer. Total $1,307,065 (Direct
$887,500; Indirect $419,565).
4. 07/01/09 06/30/11. NIH/NIBIB R01 EB008278, T. Minko Co-Investigator. Efficient
Cellular Delivery of Oligonucleotides. (Principal Investigator Dr. C. M. Roth, Department
of Chemical & Biochemical Engineering, Rutgers University). (Minko budget - $30,000).
5. 12/01/09 11/30/12. National Science Foundation Grant #0933966, T. Minko Co-Principal
Investigator. Novel Self Assembly of siRNA for Efficient and Safe Delivery. (Principal
Investigator Dr. H. He, Department of Chemistry, Newark, Rutgers University). Total -
$125,000 (Direct $80,906, Indirect $44,094).
6. 07/01/10 086/30/12. Department of Defense Lung Cancer Research Program LC090304, T.
Minko Co-Investigator (Principal Investigator Dr. O. Taratula, Postdoctoral Research
Associate working under the supervision of Dr. Minko). Innovative Strategy for Treatment of
Lung Cancer: Inhalatory Co-Delivery of Anticancer drugs and siRNA for Suppression of
Cellular Resistance. Total $150,000.
7. 12/01/06 11/30/10. United States Israel Binational Science Foundation (BSF) grant #
2005237, T. Minko US Principal Investigator, Dr. A. Rubinstein Israel Principal
Investigator. Targeting Neoplastic Tissues with Multifunctional Saccharidic Platforms
Loaded with Model Anticancer Peptides: A New Approach in Adjuvant Treatment of
Microscopic Diseases. Total $180,000.
Pending
1. 9/01/10 08/31/15. NIH/NCI U54 Center for Translational Cancer Nanomedicine, T. Minko
Leader of Project 4. Combination Nanotherapeutic Strategies to Overcome Tumor Drug
Resistance. (Center Director V. P. Torchilin, Northeastern University). Total (Minko s
budget) $1,784,433 (Direct $1,295,000; Indirect $489,433). The NCI Council has
recommended the grant for funding.
3
Tamara Minko
2. 10/01/11 09/30/15. NIH/NCI R01, T. Minko Co-Principal Investigator. E2F1 as a Anti-
Cancer Target. (Principal Investigator Dr. J. Bertino). Total (Minko s budget) $280,820
(Direct $250,000, Indirect $30,820).
3. 10/01/11 09/30/15. NIH/NCI R01CA149370, T. Minko Co-Principal Investigator. Novel
Multifunctional Silica-Dendrimer Nanospheres for Bioimaging and Targeted Delivery of
Multiple Anticancer Drugs. (Principal Investigator T. Asefa, Rutgers, The State University
of New Jersey). Total (Minko s budget) $150,000 (Direct).
Completed
1. 09/15/06 06/30/10. NIH/NIBIB R01 EB007049, T. Minko Principal Co-Investigator.
Carrier Shape Matters: Filomicelles, Long-circulation, and the EPR effect. (Principal
Investigator Dr. D. Discher, University of Pennsylvania). Total (Minko s budget)
$300,000 (Direct $196,084; Indirect $103,916).
2. 07/07/04 07/31/09. NIH/NCI R01 CA100098, T. Minko Principal Investigator, Targeted
Proapoptotic Anticancer Drug Delivery System. Total $1,020,080 (Direct $656,000;
Indirect $364,080).
3. 4/01/07 06/30/09. The American Lung Association of New Jersey, LCD-23812-N, T.
Minko Principal Investigator. Novel Inhalatory Treatment of Resistant Lung Cancer. Total
$120,000 (Direct $120,000).
4. 11/01/08 10/31/09. Department of Defense Breast Cancer Research Program, T. Minko
Principal Investigator of subcontract. Nanospheric Chemotherapeutic and Chemoprotective
Agents. (Principal Investigator Dr. L. Sheihet, Department of Chemistry, New Brunswick,
Rutgers University). Total (Minko s budget) $35,000 (Direct $35,000).
5. 03/01/08-09/01/08. Enzon Pharmaceuticals, Inc., T. Minko Principal Investigator. In vitro
and in vivo evaluation of novel anticancer compounds. Total $20,000 (Direct $12,945;
Indirect $7,055).
6. 09/15/04 08/31/07. NIH/NIBIB R21 EB004000-02, T. Minko Principal Co-Investigator.
Worm-like Micelles for Targeted Delivery and Imaging. (Principal Investigator Dr. D.
Discher, University of Pennsylvania). Total (Minko s budget) $70,000 (Direct $45,000;
Indirect $25,000).
7. 08/01/06 07/30/07. New Jersey Commission on Science and Technology, T. Minko
Principal Investigator. Treatment of Ovarian Cancer by Intra-abdominal Application of Core-
only and Core-shell Nanoparticles with Targeting Peptides Carrying Cargoes of
Chemotherapeutics. Total $15,000 (Direct $15,000).
8. 12/15/05 12/14/06. ALZA Corporation, T. Minko Principal Investigato. Antitumor
Activity of Liposomal Prodrug of Mitomycin C. Total $80,000 (Direct $63,492; Indirect
$16,508).
4
Tamara Minko
9. 04/01/04 03/31/05. Enzon Pharmaceuticals, Inc., T. Minko Principal Investigator EPR
effect of pegylated conjugates. Total $100,000 (Direct $90,910; Indirect $9,090).
10. 07/01/03 06/30/05. The American Lung Association, RG-156-N, T. Minko Principal
Investigator. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous
suppression of multidrug resistance and antiapoptotic cellular defense. Total $70,000
(Direct $70,000).
11. 09/01/04 08/31/05, NIH R21 EB003164-01, T. Minko Principal Co-investigator, CD47-
Display on Nanomaterials a New Approach to Inhibiting Phagocytosis. (Principal
Investigator Dr. D. Discher, University of Pennsylvania). Total $49,762 (Direct
$32,001; Indirect $17,761).
12. 02/15/03 02/14/05. NMHEMC Research Foundation, T. Minko Principal Investigator.
Characterization of genetic adaptation to life at high altitude: Adaptation to chronic hypoxia,
relevance to disease at sea level. Total $20,000 (Direct $20,000).
13. 07/01/03 06/30/05. New Jersey State Commission on Cancer Research, T. Minko Co-
Investigator. Prevention of Carboplatin Drug Resistance by Selenium. (Principal Investigator
Dr. L. Rodriguez-Rodriguez, The Cancer Institute of New Jersey). Total $10,000 (Direct
$10,000).
14. 03/01/04 12/31/04. Baxter Healthcare Corp., T. Minko Principal Investigator. A novel
technology to combine anticancer drugs in a least invasive and a cost-effective manner. Total
$5,000 (Direct $5,000).
15. 07/01/02 06/30/03. The Cancer Institute of New Jersey, T. Minko Principal Investigator,
Combination of Bcl-2 antisense oligonucleotides and doxorubicin-potential use in the therapy
of breast cancer. Total $25,000.
16. 07/01/01 06/30/03. Charles and Johanna Busch Fund, T. Minko Principal Investigator.
Regulation of caspase-dependent signaling pathways of apoptosis by synthetic Bcl-2
homology 3 domain (BH3) peptide in prostate cancer cells. Total $20,000.
17. 09/01/02 12/31/03. The Blanche and Irving Laurie Foundation, T. Minko Principal
Investigator. Stem cell survival enhancement by suppression of proapoptotic cell death signal
pathways. Total $5,000.
18. 06/01/01 05/31/03. New Jersey Research Division of Physicians in Transplantation and
Kidney Disease, T. Minko Principal Investigator. Influence of immumosuppressive agents
on cellular viability and apoptosis in stem cells. Total $5,000.
19. 07/01/02 12/31/03. NMHEMC Research Foundation, T. Minko Principal Investigator.
To support research in T. Minko s laboratory. Total $15,000.
20. 04/01/97 01/31/01. NIH R01 CA51578, T. Minko Co-Investigator. A polymeric drug
delivery system for cancer therapy. (Principal Investigator Dr. J. Kopecek, University of
Utah) Total $1,115,261.
5
Tamara Minko
21. 04/01/93 03/31/94. NIH IHSEP-02, T. Minko Principal Investigator from Europe (Dr.
O. Appenzeller Principal Investigator from USA). Hypoxia, migraine and Lipin. Total
$100,000.
Awards, Honors and Recognitions:
Controlled Release Society Outstanding Pharmaceutical Paper Award, (O. Taratula, O. B.
Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. P. Pozharov, H. He, T. Minko), 2010.
Member (Elected), Board of Scientific Advisors, Controlled Release Society, 2010-Present.
The paper O. B. Garbuzenko, M. Saad, V. P. Pozharov, K. R. Reuhl, G. Mainelis, T. Minko.
New horizons in treatment of lung cancer: Combinatorial local inhalatory delivery of drugs
and suppressors of cellular resistance, Proc. Natl. Acad. Sci. USA, May 24, 2010 [Epub
ahead of print] was highlighted in PNAS Media Selections
(http://www.pnas.org/site/misc/current.shtml#lung); EurekAlert!
(http://chinese.eurekalert.org/en/pub_releases/2010-05/potn-052110.php); DOTMED NEWS
(http://www.dotmed.com/news/story/12777/); NewScientist Magasine
(http://www.newscientist.com/article/mg20627623.800-inhale-lung-chemo-to-limit-organ-
damage.html); Ecancermedicalscience (http://www.ecancermedicalscience.com/news-
insider-news.asp?itemId=1049).
New Jersey Pharmaceutical Association for Science and Technology 2010 Student
Scholarship Award (M. Zhang, Graduate Student of T. Minko), 2010.
Fellow (Elected), American Association of Pharmaceutical Scientists (AAPS) (2009).
The paper A. M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, T. Minko, H. He, Co-
delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the
Efficacy of Chemotherapy in Multidrug Resistant Cancer Cells, Small, 5, 2673-2677 (2009)
was highlighted in TopNews (http://www.topnews.in/usa/node?page=36); Bioscience
Technology (http://www.biomedicalproducts.com/News/Feeds/2010/02/disease-research-
new-developments-in-nanotechnology-tackle-the-2-bi); OneIndia
(http://news.oneindia.in/2010/02/26/nanotechnologyapproach-may-fight-problems-linked-
tochemo.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+onei
ndia-all-news+%28Oneindia+-+News%29).
AAPS Physical Pharmacy and Biopharmaceutics (PPB) Graduate Student Award (M. Zhang,
Graduate Student of T. Minko), 2009.
First Place Poster Award, The Biennial New Jersey Pharmaceutical Conference (M. Zhang,
O. Garbuzenko, L. Rodriguez, T. Minko), 2009.
Second Place Poster Award, The Biennial New Jersey Pharmaceutical Conference (O.
Taratula, O. Garbuzenko, Z. Wang, G. Mainelis, T. Minko), 2009.
The New Jersey Cancer Research Award for Scientific Excellence (O. Taratula, O. B.
Garbuzenko, R. Savla, H. He, T. Minko), 2009.
Dr. T. Minko s name appears as Minyailenko due to the change of the last name.
6
Tamara Minko
The paper M. Saad, O. B. Garbuzenko, T. Minko, Co-delivery of siRNA and an anticancer
drug for treatment of multidrug resistant cancer, Nanomedicine, 3, 761-776 (2008) was
highlighted in LeadDiscovery (http://www.leaddiscovery.co.uk/articles/19025451/
dailyupdate).
The paper M. Saad, O. B. Garbuzenko, E. Ber, P. Chandna, J. J. Khandare, V. P. Pozharov,
T. Minko, Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the
most efficient for tumor-specific treatment and imaging?, J. Control. Release, 130, 107-114
(2008) was highlighted in Cover Story by the Editor-in-Chief of the Journal (K. Park, J.
Control. Release, 130, 139, 2008) and the figure from the paper was selected for the cover
page of the issue.
The paper M. L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, T. Minko, Surface
Modified and Internally Cationic Polyamidoamine Dendrimers for Efficient siRNA Delivery,
Bioconjugate Chem., 19, 1396-403 (2008) was highlighted in Pharmacy Choice News
(http://www.pharmacychoice.com/news/article.cfm?Article_ID=122774).
Controlled Release Society Outstanding Pharmaceutical Paper Award, (S. Betigeri, O. B.
Garbuzenko, T. Minko), 2008.
AAPS Biotechnology Graduate Student Award (P. Chandna, Graduate Student of T. Minko),
2008.
AAiPS Research Award for the Contribution to Research in the Pharmaceutical Sciences (P.
Chandna, Graduate Student of T. Minko), 2008.
Controlled Release Society Outstanding Student Poster Award (P. Chandna, Graduate
Student of T. Minko), 2008.
Gallo Award for Scientific Excellence, Presented by The Cancer Institute of New Jersey for
Outstanding Cancer Research (M. Saad, Graduate Student of T. Minko), 2008.
Gallo Award for Scientific Excellence, Presented by The Cancer Institute of New Jersey for
Outstanding Cancer Research (O. Taratula, Graduate Student of T. Minko and H. He), 2008.
Graduate Student Award, 21st Annual International Symposium Frontiers of
Nanotechnology & Biotechnology: Integration and Invention (O. Taratula, Graduate
Student of T. Minko and H. He), 2008.
Faculty Academic Service Increment Awards, Rutgers, the State University of New Jersey
(2001, 2002, 2004 2005, and 2007).
AAPS Biotechnology Graduate Student Award (S. Betigeri, Graduate Student of T. Minko),
2007.
AAiPS Research Award for the Contribution to Research in the Pharmaceutical Sciences (S.
Betigeri, Graduate Student of T. Minko), 2007.
The Outstanding Excellence Awards for the best paper presentations in the 27th Anniversary
Conference, GRASP 2007 (Oleh Taratula, Graduate Student of T. Minko and H. He), 2007.
7
Tamara Minko
The paper J. J. Khandare, T. Minko, Polymer-drug conjugates: Progress in polymeric
prodrugs, Prog. Polym. Sci., 31, 359-397 (2006) was listed in Top 25 Hottest Articles of
Progress in Polymer Science Journal by ScienceDirect.
The paper R. I. Pakunlu, Y. Wang, M. Saad, J. J. Khandare, V. Starovoytov, T. Minko, In
vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer
drug, J. Controlled Rel., 114, 153-162 (2006) was listed in Top 25 Hottest Articles of
Journal of Controlled Release by ScienceDirect.
The First Place Advanced Drug Delivery Charles A. Stevens Memorial Award at the
Philadelphia Pharmaceutical Forum (R. I. Pakunlu, Graduate Student of T. Minko), 2006.
The paper S. S. Dharap, Y. Wang, P. Chandna, J. J. Khandare, B. Qiu, S. Gunaseelan, P. J.
Sinko, S. Stein, A. V. Farmanfarmanian and T. Minko, Tumor-specific targeting of an
anticancer drug delivery system by LHRH peptide, Proc. Natl. Acad. Sci. USA, 102, 12962-
12967 (2005) was selected as Research Highlights by Nature Reviews Cancer (E.
Hutchinson, Efficient delivery, Nature Reviews Cancer, 5, 10, 2005, P. 759).
The paper S. S. Dharap, Y. Wang, P. Chandna, J. J. Khandare, B. Qiu, S. Gunaseelan, P. J.
Sinko, S. Stein, A. V. Farmanfarmanian and T. Minko, Tumor-specific targeting of an
anticancer drug delivery system by LHRH peptide, Proc. Natl. Acad. Sci. USA, 102, 12962-
12967 (2005) was highlighted by Nature News with article titled: Unerring hormone delivers
cancer drug. News@Nature. 22 Aug 2005.
http://www.nature.com/news/2005/050822/full/050822-2.html) and by Reuters
(http://www.oncolink.org/resources/article.cfm?c=3&s=8&ss=23&id=12229&month=08&ye
ar=2005).
AAiPS Research Award for the Contribution to Research in the Pharmaceutical Sciences (P.
Chandna, Graduate Student of T. Minko), 2005.
The First Place Biotechnology Charles A. Stevens Memorial Award at the Philadelphia
Pharmaceutical Forum (Y. Wang, Graduate Student of T. Minko), 2005.
The Outstanding Excellence Awards for the best paper presentations in the 25th Anniversary
Conference, GRASP 2005 (Seema Betigeri and Pooja Chandna, Graduate Students of T.
Minko), 2005.
The First Place Biotechnology Charles A. Stevens Memorial Award at the Philadelphia
Pharmaceutical Forum (Y. Wang, Graduate Student of T. Minko), 2005.
The paper S. S. Dharap, B. Qiu, G. Williams, P. J. Sinko, S. Stein, T. Minko, J. Controlled
Rel., 91, 61-73 (2003) was selected as the Highlights by Controlled Release Society
Newsletter (CRS Newsletter, Vol. 20, No. 3: page 21, 2003).
The paper S. S. Dharap and T. Minko, Pharm. Res., 20, 889-896 (2003) was selected as the
Highlights by AAPS Newsmagazine, the official publication of the American Association
of Pharmaceutical Scientists (AAPS Newsmagazine, Vol.6, No 6: pp.38-39, 2003).
AAPS Biotechnology Graduate Student Award (S. S. Dharap, Graduate Student of T.
Minko), 2003.
8
Tamara Minko
Award for an Outstanding Achievement from International Journal of Oncology, Oncology
Reports and International Journal of Molecular Medicine, 2002.
Journal of Applied Physiology of the American Physiological Society chose the paper T.
Minko at al., J. Appl. Physiol., 93, 1550-1560 (2002) as the Selected Contribution and the
Highlighted Topics of Editorial Commentary.
Charles A. Stevens Memorial Awards (The First Place) at the Philadelphia Pharmaceutical
Forum (S. S. Dharap, Graduate Student of T. Minko), 2003.
AAiPS Research Award for the Contribution to Research in the Pharmaceutical Sciences (S.
S. Dharap, Graduate Student of T. Minko), 2002.
Charles A. Stevens Memorial Awards (The Second Place) at the Philadelphia Pharmaceutical
Forum (S. S. Dharap, Graduate Student of T. Minko), 2002.
The Jorge Heller Journal of Controlled Release/Controlled Release Society Outstanding
Paper Award for 1998 year (T. Minko, V. Pozharov, P. Kopeckova, J. Kopecek), 1998.
Awards of the Biology and Theoretical Medicine Section of the Ukrainian Academy of
Sciences, 1984, 1988, 1993.
Recent Professional Activities:
Service to the Professional/Scientific Organizations
Member (Elected), Board of Scientific Advisors, Controlled Release Society, 2010-Present.
Program Chair, Bioactive Materials, 36th Annual Meeting of the Controlled Release Society,
Copenhagen, Denmark, 2008-2009.
Member, Controlled Release Society Pharmaceutical Outstanding Paper Award
Subcommittee, 2008-Present.
Abstract Reviewer, Annual Meetings of the American Association of Pharmaceutical
Scientists, 2001-Present; Annual Meetings of the Controlled Release of Bioactive Materials,
2003-Present.
Service to the Scientific Journals
Member, Editorial Advisory Board, Molecular Pharmaceutics, 2010-Present.
Member, Editorial Advisory Board, Drug Delivery and Translational Research, 2010-
Present.
Editor, Pharmaceutical Research, 2008-Present.
Guest Editor, Theme Issue Intracellular Drug Delivery, Pharmaceutical Research, 2007.
Member, Editorial Board, Recent Patents on Drug Delivery and Formulation, 2007-
Present.
Member, Editorial Board, Critical Reviews in Therapeutic Drug Carriers System, 2005-
Present.
Member, Editorial Advisory Board, Pharmaceutical Research, 2005-2008.
9
Tamara Minko
Ad Hoc Journal Reviewer, Nature Medicine, Cancer Research, Nature Reviews Drug
Discovery, Advanced Drug Delivery Review, Journal of Pharmacology and Experimental
Therapy, Journal of Controlled Release, Pharmaceutical Research, Molecular Pharmaceutics,
Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, European
Journal of Pharmaceutical Sciences, Journal of Drug Targeting, Nanomedicine, Cancer
Letters, Cancer Therapy, Anti-Cancer Drug, Lung Cancer, Cancer Detection and Prevention,
Biomacromolecules, American Journal of Drug Delivery, Journal of Biomedical Materials
Research, Journal of Bioactive and Compatible Polymers, Biopharmaceutics and Drug
Disposition, Neoplasia, Expert opinion on Drug Delivery, Liver International, European
Journal of Medicinal Chemistry, AAPS PharmSci, BioTechniques, Medical Science Monitor,
2000-Present.
Service to the National Institutes of Health, Department of Defense, American Heart
Association and International Scientific Review Panels
Member, NIH/NCI Study Section Preclinical Pharmacokinetic and Pharmacological Studies
of Anticancer and Other Therapeutic Agents (RFP N01-CM-07014-39), 2010-Present.
Member, Ad Hoc NIH Study Section Nanotechnology (NANO), 2009.
Member, Ad Hoc NIH Special Emphasis Panel Study Section (ZRG1 BST-Z (10) B), 2007.
Member, Ad Hoc NIH Study Section Discovery and Development (DHHS), 2007 2008.
Member, NIH Study Section Bioengineering, Technology and Surgical Sciences (BTSS),
2006 2010.
Member, Ad Hoc NIH Special Emphasis Panel Study Section Nanotechnology and
Nanosciences (ZRG1 BCMB-R (50)), 2005.
Member, Ad Hoc NIH/NCI Special Emphasis Panel Study Section Cancer Nanotechnology
Partnerships (ZCA1 SRRB-C), 2005.
Member, Ad Hoc NIH Special Emphasis Panel Study Section Chemical and Bioanalytical
Sciences (ZRG1 F04A (20)), 2005.
Member, Ad Hoc NIH Special Emphasis Panel Study Section ZRG1 SBIB-G (03), 2004.
Member, Ad Hoc NIH Study Section Bioengineering, Technology and Surgical Sciences
(BTSS), 2003.
Member, American Heart Association Bioengineering and Biotechnology 1 Peer Review
Study Group, 2006 2007.
Member, Department of Defense Ovarian Cancer Panel #2 (OC-2), 2006.
Member, United States Israel Binational Science Foundation (BSF), 2007 2008.
Member, International Review Panel Charged with Assisting the Portuguese Foundation for
Science and Technology in evaluating research proposals in areas of Pharmacology,
Pharmaceutical Sciences and Biomaterials (Primary reviewer Drug Delivery; Secondary
reviewer - Cancer Pharmacology), 2001-2005.
Service to Rutgers University
10
Tamara Minko
Vice Chair, The University s Animal Care and Facilities Committee, Rutgers, The State
University of New Jersey (2008 Present).
Member, Graduate School Biological Sciences Area Committee, Rutgers, The State University
of New Jersey (2008 Present).
Acting Director, The Graduate Program of Pharmaceutical Science, Rutgers, The State
University of New Jersey (2008).
Member, The Search Committee for the Dean of the Graduate School of New Brunswick,
Rutgers, The State University of New Jersey (2007 2008).
Member, The Search Committee for the Dean of the Ernest Mario School of Pharmacy, Rutgers,
The State University of New Jersey (2006 2007).
Member, The University s Animal Care and Facilities Committee, Rutgers, The State University
of New Jersey (2004 Present).
Service to Ernest Mario School of Pharmacy
Vice-Chair, Curriculum, Educational Goal and Outcomes Assessment Committee, Ernest Mario
School of Pharmacy (2008 Present).
Member, Budget and Policy Committee (2008 Present).
Member, Space and Physical Resources Committee (2008 Present).
Member, Organization and Administration Self-Study Focus Group (2006-2007).
Member, Advisory Committee of Appointment and Promotions (2005 Present).
Member, Ad Hoc Committee: Self Study Document for External Review, Ernest Mario School
of Pharmacy (2002 2003).
Member, Curriculum, Educational Goal and Outcomes Assessment Committee, Ernest Mario
School of Pharmacy (2000 2007).
Service to the Department of Pharmaceutics and Graduate Program of Pharmaceutical
Science
Member, Admission and Curriculum Committee (2005 Present).
Member, Graduate Students Committees (Independent Research Proposal, Thesis Proposal,
Thesis Defense) (n = 80).
Societies:
American Chemical Society, since 2006
The International Society for Preventive Oncology, 2002-2006
American Association of Pharmaceutical Scientists, since 1999
American Association of Colleges of Pharmacy, since 1999
Controlled Release Society, since 1998
Mountain West Chapter Society of Toxicology, 1998-2000
11
Tamara Minko
American Association for Clinical Chemistry, 1995-1996
International Society for Adaptive Medicine, 1990-1993
International Society for Pathophysiology, 1990-1993
Ukrainian Physiological Society, 1984-1993
Ukrainian Society for Pharmacology and Toxicology, 1984-1993
Conference Organizations, Presentations, Lectures and Seminars (2000-Present):
Conference Organizer, Section Chair/Moderator (12)
1. Program Chair, the 36th Annual Meeting of the Controlled Release Society, Copenhagen,
Denmark (2008-2009).
2. Chair, Session Inhaled Medicine, the 36th Annual Meeting of the Controlled Release
Society, Copenhagen, Denmark, July 22, 2009.
3. Section Chair, 2008 NSTI Nanotech 2008 11th Annual Meeting, NCI/NSTI Special
Symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment, Boston,
MA, June 4, 2008.
4. Chair and Moderator, Section Nanotechnology Approaches for Bioimaging, the Fourth
International Nanomedicine and Drug Delivery Symposium, Omaha, Nebraska, October 9,
2006.
5. Chair, Section Drug Delivery Systems, the 7th International Biorelated Polymers
Symposium at the 232nd American Chemical Society Meeting, San Francisco, California,
September 12, 2006.
6. Chair, Section Biomimetic Carriers, the 33rd Annual Meeting of the Controlled Release
Society, Vienna, Austria, July 23, 2006.
7. Conference Organizer and Chair, the Biennial New Jersey Pharmaceutical Conference of
2005 Contribution of Women in the Pharmaceutical Sciences, East Brunswick, NJ,
October 6, 2005.
8. Chair and Moderator, Section Targeted Delivery of Anticancer Agents, the Third
International Nanomedicine and Drug Delivery Symposium, Baltimore, Maryland,
September 27, 2005.
9. Chair and Moderator, Section Receptor Mediated Drug Targeting, 31st International
Symposium on Controlled Release of Bioactive Materials, Honolulu. Hawaii, June 12, 2004.
10. Chair, Section Pharmacology and Biochemistry, 8th World Congress on Advances in
Oncology and 6th International Symposium on Molecular Medicine, Hersonissos, Crete,
Greece, October 16, 2003.
11. Chair, Section Pharmacology and Biochemistry, 7th World Congress on Advances in
Oncology and 5th International Symposium on Molecular Medicine, Hersonissos, Crete,
Greece, October 10, 2002.
12. Chair and Member of the Student Poster Session Committees for the following conferences:
Toward the Development of Drug Delivery Systems, 2nd Annual Meeting of Italian
Chapter of AAPS, Perugia, Italy, March 7, 2008.
The Fifth International Nanomedicine and Drug Delivery Symposium, Boston, MA,
November 2, 2007.
12
Tamara Minko
GRASP 2007, 27th Annual Meeting, New Brunswick, NJ, June 1-3, 2007.
Targeted Nanocarriers and Therapeutics, Institute for Translational Medicine and
Therapeutics, The University of Pennsylvania School of Medicine, Philadelphia, PA,
November 16, 2006.
Plenary/Invited Lectures and Seminars (78)
1. Nanotechnology Strategies to Overcome Limitations in Cancer Treatment, Particles 2010:
Medical/Biochemical Diagnostic, Pharmaceutical, and Drug Delivery Applications of
Particle Technology, May 23, 2010, Lake Buena Vista, FL.
2. Nanotechnology Strategies to Overcome Limitations in Cancer Chemotherapy, Department
of Pharmaceutical Sciences, Wayne State University, April 28, 2010, Detroit, MI.
3. Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and
Challenges, New York Society of Cosmetic Chemists (NYSCC) Spring Seminar, April 21,
2010, West Orange NJ.
4. Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and
Challenges, Clinical Applications of Quantum Dot and Nanoparticle Technology,
University of Illinois at Chicago Center for Clinical and Translational Science (CCTS), April
13, 2010, Chicago, IL.
5. Mechanisms of Cellular Drug Resistance and Strategies to Overcome It, Symposium on
Biomedical Polymers for Drug Delivery, March 27, 2010, Salt Lake City, UT.
6. Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and
Challenges, University of Wisconsin, March 17, 2010, Madison, WI.
7. Nanotechnology Strategies to Overcome Limitations in Cancer Chemotherapy, F.
Hoffmann-La Roche Ltd, January 29, 2010, Nutley, NJ.
8. New horizons in treatment of lung cancer: Combinatorial liposomal inhalation delivery of
drugs and suppressors of cellular resistance, Liposome advances: Recent trends and
progress, December 13, 2009, London, UK.
9. Targeted multifunctional nanocarriers for tumor treatment and imaging, Annual Meeting of
the American Association of Pharmaceutical Scientists, November 11, 2009, Los Angeles,
CA.
10. Inhalatory co-delivery of anticancer drugs and antisense oligonucleotides/siRNA for lung
cancer treatment, 35th Annual Meeting of the Controlled Release Society, July 22, 2009,
Copenhagen, Denmark.
11. Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and
Challenges, 41st Annual Pharmaceutics Graduate Student Research Meeting Globalization
of the Pharmaceutical Industry, June 26, 2009, Purdue University, West Lafayette, IN.
12. Nanotechnology Strategies to Overcome Limitations in Drug Delivery: Opportunities and
Challenges, AAPS Workshop on Evolving Science and Technology in Physical Pharmacy
and Biopharmaceutics, May 15, 2009, Baltimore, MD.
13
Tamara Minko
13. Receptor Targeted Nanocarriers for Tumor-Specific Treatment and Imaging, 14th
International Symposium on Recent Advances in Drug Delivery Systems, February 18, 2009,
Salt Lake City, UT.
14. Multifunctional Nanotherapeutics for Cancer Treatment, American Association for Cancer
Research American Chemical Society Joint Conference on: Chemistry in Cancer Research:
A Vital Partnership in Drug Discovery and Development, February 10, 2009, New Orleans,
LA.
15. Receptor Targeted Nanocarriers for Tumor-Specific Treatment and Imaging, The Provost
Interdisciplinary Seminar Series on Targeted Therapeutics and Drug Delivery Systems, The
University of Pennsylvania School of Medicine, Philadelphia, PA, January 14, 2009.
16. Receptor-targeted nanocarriers for tumor-specific treatment and imaging, Birck
Nanotechnology Center, Purdue University, West Lafayette, IN, December 11, 2008.
17. Efficient Co-Delivery of siRNA/Antisense Oligonucleotides and Drug for Lung Cancer
Treatment, 36th Annual Scientific Session of the New Jersey Thoracic Society, New
Brunswick, NJ, June 6, 2008.
18. Nanocarriers for Tumor-Targeted Drug Delivery, 2008 NSTI Nanotech 2008 11th Annual
Meeting, NCI/NSTI Special Symposium on Nanotechnology for Cancer Prevention,
Diagnosis and Treatment, Boston, MA, June 4, 2008.
19. Targeted Multifunctional Nanocarriers for Tumor Treatment and Imaging, Toward the
Development of Drug Delivery Systems, 2nd Annual Meeting of Italian Chapter of AAPS,
Perugia, Italy, March 7, 2008.
20. Targeted Multifunctional Nanocarriers for Intracellular Drug Delivery, University of
Ferrara, Italy, March 6, 2008.
21. Targeted Multifunctional Nanocarriers for Tumor Treatment and Imaging, School of
Pharmacy, University of Rhode Island, Kingston, RI, May 15, 2008.
22. Tumor Targeted Anticancer Prodrugs, Annual Meeting of the American Association of
Pharmaceutical Scientists, San Diego, CA, November 15, 2007.
23. Targeted Multicomponent Nanocarriers for Cancer Treatment and Diagnostics, The Fifth
International Nanomedicine and Drug Delivery Symposium, Boston, MA, November 2,
2007.
24. Multifunctional Drug Delivery System for Inhalatory Treatment of Lung Cancer, The
Biennial New Jersey Pharmaceutical Conference of 2007, New Brunswick, NJ, October 5,
2007.
25. Targeted Multifunctional Nanocarriers for Intracellular Drug Delivery, Department of
Pharmaceutics at the University of Minnesota, Minneapolis, MN, September 20, 2007.
26. Targeted multicomponent nanocarriers in cancer treatment, the 6th Annual Meeting of the
Israeli Chapter of the Controlled Release Society on September 5, 2007, Cesaria, Israel.
27. Targeted Multifunctional Drug Delivery Systems for Cancer Treatment and Imaging
Chemistry and Chemical Biology Department at Stevens Institute of Technology, Hoboken,
NJ., September 12, 2007.
14
Tamara Minko
28. Tumor-Specific Targeting of Drug Delivery Systems for Cancer Therapy and Imaging,
34th Annual Meeting of the Controlled Release Society, Long Beach, CA, July 11, 2007.
29. Complex Liposomal Drug Delivery System for Inhalatory Treatment of Lung Cancer, 35th
Annual Scientific Session of the New Jersey Thoracic Society, New Brunswick, NJ, June 1,
2007.
30. Targeted Multifunctional Nanocarriers for Intracellular Drug Delivery, Department of
Chemistry, Newark, Rutgers, The State University of New Jersey, Newark, NJ, March 30,
2007.
31. Receptor Targeting of Polymer Therapeutics and Imaging Agents to Tumor, International
Symposium on Polymer Therapeutics ISPT-07, Berlin, Germany, February 20, 2007.
32. Tumor-Specific Targeting of Drug Delivery Systems, Novartis Pharmaceuticals, East
Hanover, NJ, November 17, 2006.
33. Targeted Nanocarriers for Intracellular Drug Delivery, Targeted Nanocarriers and
Therapeutics, Institute for Translational Medicine and Therapeutics, The University of
Pennsylvania School of Medicine, Philadelphia, PA, November 16, 2006.
34. Tumor - Targeting Liposomal Complex for Short Interfering RNA Delivery, Georgetown
University Medical Center, Washington DC, October 24, 2006.
35. Targeted Polymeric Prodrug with Multivalent Components for Cancer Therapy, the 7th
International Biorelated Polymers Symposium at the 232nd American Chemical Society
Meeting, San Francisco, CA, September 12, 2006.
36. Molecular targeting of drug delivery system to lung cancer, 34th Annual Scientific Session
of New Jersey Thoracic Society, New Brunswick, NJ, June 2, 2006.
37. Targeted Proapoptotic Drug Delivery System for Chemotherapy of Ovarian Cancer, The
Cancer Institute of New Jersey, New Brunswick, NJ, May 5, 2006.
38. Extracellular and intracellular molecular targeting of drug delivery system to cancer,
College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, March 31, 2006.
39. Targeted anticancer polymeric prodrugs, Abbott Laboratories, Abbott Park, IL, March 23,
2006.
40. Complex drug delivery composition for treating cancer, Department of Pharmaceutics and
Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, February 27, 2006.
41. Advances in targeted drug delivery for cancer treatment, Bristol-Myers Squibb Co., New
Brunswick, NJ, February 3, 2006.
42. Targeted drug delivery systems for cancer therapy, Department of Biopharmaceutical
Sciences, University of Illinois at Chicago, Chicago IL, January 11, 2006.
43. Advanced targeted drug delivery systems for cancer therapy, International Conference on
Advances in Pharmaceutical Research and Technology, Mumbai, India, November 25-29,
2005.
44. Novel approaches in anticancer drug delivery, The Biennial New Jersey Pharmaceutical
Conference of 2005 Contribution of Women in the Pharmaceutical Sciences, East
Brunswick, NJ, October 6, 2005.
15
Tamara Minko
45. Delivery system for remediation of cellular hypoxic damage, Third International
Nanomedicine and Drug Delivery Symposium, Baltimore, MD, September 26-27, 2005.
46. Molecular targeting of drug delivery systems to cancer, College of Pharmacy, Howard
University, Washington, DC, November 4, 2004.
47. Targeted delivery of anticancer drugs and peptides by polyethylene glycol conjugates, 7th
Symposium on Biomaterials Science, New Brunswick, NJ, October 21-22, 2004.
48. Extracellular and intracellular molecular targeting of drug delivery system to cancer cells,
World Conference on Dosing of Antiinfectivnes Dosing the Magic Bullets, Nurnberg,
Germany, September 9-11, 2004.
49. A novel multicomponent delivery system to enhance the efficacy of lung cancer therapy,
32nd Annual Scientific Section of the New Jersey Thoracic Society, New Brunswick, NJ,
June 4, 2004.
50. Targeted proapoptotic anticancer drug delivery system, College of Pharmacy, University of
Maryland, Baltimore, MD, March 3, 2004.
51. Molecular targeting of drug delivery systems to cancer cells by peptides and antisense
oligonucleotides, College of Pharmacy, University of Kentucky, Lexington, KY, February
27, 2004.
52. Molecular targeting of cellular resistance in cancer, 8th World Congress on Advances in
Oncology and 6th International Symposium on Molecular Medicine, Crete, Greece, October
16, 2003.
53. Multicomponent drug delivery system for enhancing the efficacy of cancer chemotherapy,
Meeting of the New Jersey Center for Biomaterials, New Brunswick, NJ, September 17,
2003.
54. Molecular targeting of drug delivery systems to cancer cells by peptides and antisense
oligonucleotides, Department of Biopharmaceutical Sciences, University of Illinois at
Chicago, Chicago IL, April 2, 2003.
55. Genetic adaptation to life at high altitude: Adaptation to chronic hypoxia, relevance to
disease at sea level, University of Lima, Lima, Peru, March 14, 2003.
56. Advanced targeted drug delivery systems for cancer therapy, Myriad Genetics, Inc., Salt
Lake City, UT, March 4, 2003.
57. Molecular targeting of drug delivery systems to cancer cells by peptides and antisense
oligonucleotides, EOHSI, Piscataway, NJ, February 6, 2003.
58. Targeted proapoptotic drug delivery systems in cancer chemotherapy, 7th World Congress
on Advances in Oncology and 5th International Symposium on Molecular Medicine,
Hersonissos, Crete, Greece, October 11, 2002.
59. Targeted proapoptotic drug delivery systems in cancer chemotherapy, Cancer Institute of
New Jersey (Breast Cancer Research Program), New Brunswick, NJ, May 2002.
60. Advanced drug delivery systems in cancer chemotherapy, The Screening Technologies
Branch of the Developmental Therapeutics Program in Drug Discovery and Development,
National Cancer Institute, Frederick, MD, March 2002.
16
Tamara Minko
61. Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic
cellular defense, 6th International Symposium on Predictive Oncology and Intervention
Strategies, Pasteur Institute, Paris, France, February 2002.
62. Novel drug delivery systems for cancer therapy, Salvona, Dayton, NJ, January 2002.
63. Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic
cellular defense, GPCC Retreat, The Center for Advanced Biotechnology and Medicine,
UMDNJ, Piscataway, NJ, December 2001.
64. Advanced drug delivery systems in cancer chemotherapy, VectraMed, Princeton, NJ,
December 2001.
65. Enhancing the efficacy of anticancer drugs using multicomponent advanced drug delivery
system, The Cancer Institute of New Jersey, New Brunswick, NJ, December 2001.
66. Advanced drug delivery systems in cancer chemotherapy, Pharmaceutics Conference 2001,
East Brunswick, NJ, November 2001.
67. A polymer drug delivery system for cancer therapy, New Jersey Center for Biomaterials,
Piscataway, NJ, June 1, 2001.
68. Antitumor activity and cell death signaling pathway of free and polymer-bound doxorubicin.
The PH 890, Pharmacy Seminar (Pharmaceutics, Spring 2001), Philadelphia College of
Pharmacy, University of the Science, Philadelphia, PA, April 27, 2001.
69. Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin, ENZON, Inc.,
Piscataway, NJ, November 16, 2000.
70. Mechanism of anticancer action of HPMA copolymer-bound doxorubicin, 40th
Microsymposium "Polymers in Medicine", Czech Republic, July 2000, Special Lecture #4.
71. Cell death signaling pathways and antitumor activity polymer-bound drugs, Department of
Pharmacology and Toxicology, School of Pharmacy, University of Utah, Salt Lake City, UT,
November 1999.
72. Adaptation to moderate stress increases the resistance to severe hypoxia, International
Symposium on High-Altitude Medicine, Matsumoto, Japan, September 1992.
73. The criterion for the selection of hypoxic impacts for interval hypoxic training,
International Symposium on Interval Hypoxic Training: Efficiency and Mechanisms of
Action, Kiev, Ukraine, September 1992.
74. Oxygen supply-consumption ratio as the criterion of tissue hypoxia, Hypoxia and
Ischemia: Basic and Applied Aspects, Berlin, Germany, September 1991.
75. Primary and secondary disturbances of acid-base homeostasis, Acid-base and Thermal
Homeostasis, Syktyvkar, Russia, February 1991.
76. Influence of adaptation to high altitude hypoxia on the resistance of an organism to oxygen
deficiency and stress, Functional Reserves and Adaptation, Kiev, Ukraine, September 1990.
77. Peculiarities of organism oxygen supply under bronchial asthma in mountains, Usage of
Mountain Climate to Treatment and Prophylaxis, Nalchik, Russia, April 1988.
17
Tamara Minko
78. The conformity between oxygen mass transfer and its consumption during hypoxia of
different genesis, Regulation of Respiration and Gas Mass Transfer in the Organism,
Leningrad, Russia, April 1985.
Oral (Podium) Presentations (20)
1. Straight to the Target: A Novel Polymeric Prodrug with Multivalent Components for Cancer
Therapy, 33rd International Symposium on Controlled Release of Bioactive Materials,
Vienna, Austria, July 22-26, 2006.
2. Hypoxia Inducible Factor - Targeted Anticancer Prodrug, 32nd International Symposium on
Controlled Release of Bioactive Materials, Miami, FL, June 18-22, 2005.
3. Targeted proapoptotic anticancer drug delivery system, 31st International Symposium on
Controlled Release of Bioactive Materials, Honolulu. HI, June 15, 2004.
4. Novel Targeted Drug Delivery Systems Combining Anticancer Drug, Targeting Moiety and
Suppressors of Multidrug Resistance and Antiapoptotic Cellular Defense, CRS Winter
Symposia & 11th International Symposium on Recent Advances in Drug Delivery Systems,
Salt Lake City, UT, March 3-6, 2003.
5. Molecular targeting of drug delivery systems for ovarian carcinoma therapy, International
Symposium on Tumor Targeted Delivery Systems (CRS & NIH), Bethesda, MD, September
24, 2002.
6. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense with
liposomes containing doxorubicin and antisense oligonucleotides targeting MDR1 and BCL-
2 mRNA, 29th Annual Meeting of the Controlled Release Society, Seoul, Korea, July 25,
2002.
7. Delivery of synthetic BCL-2 homology 3 domain (BH3) peptide by fusion with the
Antennapedia internalization sequence in combination with an antiapoptotic drug
concurrently enhances apoptosis and inhibits antiapoptotic defenses in human ovarian
carcinoma, Gordon Research Conference: Drug Carriers in Medicine and Biology, Ventura,
CA, February 2002.
8. Role of caspases in cellular signal transduction pathways of apoptosis induced by free and
HPMA copolymer-bound doxorubicin, The 27th International Symposium on Controlled
Release of Bioactive Materials, Paris, France, July 2000.
9. Cell death signaling pathways, toxicity and antitumor activity of free and polymer-bound
doxorubicin, Molecular Genetics in Toxicology, 17th Annual Meeting of Mountain West
Chapter of Society of Toxicology, Breckenridge, CO, September 1999.
10. EPR effect, multidrug resistance and the efficacy of HPMA copolymer-bound adriamycin in
solid tumors with high vascularization, The 26th International Symposium on Controlled
Release of Bioactive Materials, Boston, MA, June 1999.
11. Peculiarities of apoptosis induction and cell metabolism in human ovarian carcinoma cell
lines exposed to free and HPMA copolymer bound adriamycin, The 25th International
Symposium on Controlled Release of Bioactive Materials, Las Vegas, NV, June 1998.
18
Tamara Minko
12. Mechanisms of the increase in the work load after preliminary adaptation to
intermittent hypoxia and training, III World Congress of ISAM, Tokyo, Japan, May
1993.
13. Towards a new way to elevate the resistance against damaging environmental impacts, 1st
American Ukrainian Workshop "Health Care: Clinical and Basic Research", Kiev,
Ukraine, June 1993.
14. Hypoxic acid-base changes, lipid peroxidation and oxygen supply-consumption ratio, 7th
International Hypoxia Symposium, Lake Louise, Canada, February 1991.
15. Adaptation to high altitude limits tissue hypoxia and lipid peroxidation under severe acute
environmental hypoxia, International Congress of Mountain Medicine, Crans-Montana,
Switzerland, April 1991.
16. Interrelation of lipid peroxidation and tissue hypoxia under hypoxic states of different
genesis, Constituent Congress of International Society for Pathophysiology, Moscow,
Russia, May 1991.
17. Role of primary disturbances of blood buffer capacity in the compensation of metabolic
acidosis, Actual Problems of Pathology of Respiration, Kujbyshev, Russia, November 1989.
18. Factors which determine resistance of blood active reaction under hypoxia, Reactivity and
Resistance: Fundamental and Applied Aspects, Kiev, Ukraine, May 1987.
19. Respiration, circulation, blood acid-base balance and oxygen regimen of organism in
women-arid zone lenders with iron deficit anemia under the influence of mountain climate,
Human Adaptation in Different Climatogeographic and Industrial Environment, Novosibirsk,
Russia, June 1981.
20. Peculiarities of blood buffering properties and acid base status in girls with secondary
anemia, Annual Meeting of Physiological Society: Special and Clinical Physiology of
Hypoxic States, Kiev, Ukraine, November 1979.
Oral (Podium) Presentations of the Graduate Students, Postdoctoral Fellows and
Researchers from Minko s Lab Since 2000 (12)
1. Combinatorial local inhalatory treatment of lung cancer, Innovations in Drug Delivery
Technologies, The Biennial New Jersey Pharmaceutical Conference of 2009, November 20,
2009, Piscataway, NJ (O. Garbuzenko, M. Saad, V. P. Pozharov, K. R. Reuhl, G. Mainelis,
T. Minko).
2. Dendrimers as Potential siRNA Delivery Vehicles for Efficient Cancer Therapy,
Innovations in Drug Delivery Technologies, The Biennial New Jersey Pharmaceutical
Conference of 2009, November 20, 2009, Piscataway, NJ (O. Taratula, O. Garbuzenko, T.
Minko).
3. Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most effective
for tumor specific treatment and imaging? in 35th Annual Meeting of the Controlled
Release Society, July 12-16, 2008, New York, NY (M. Saad, O. B. Garbuzenko, E. Ber, P.
Chandna, J. J. Khandare, V. P. Pozharov, T. Minko).
19
Tamara Minko
4. A novel targeted proapoptotic drug delivery system for efficient anticancer therapy in 35th
Annual Meeting of the Controlled Release Society, July 12-16, 2008, New York, NY (P.
Chandna, M. Saad, Y. Wang, E. Ber, J. Khandare, A. A. Vetcher, V. A. Soldatenkov, T.
Minko).
5. JNK1 as a molecular target to limit cellular damage under hypoxia in 35th Annual Meeting
of the Controlled Release Society, July 12-16, 2008, New York, NY (S. Betigeri, O. B.
Garbuzenko, T. Minko).
6. Noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research in
The Annual Retreat on Cancer Research in New Jersey, May 28, 2008, Piscataway, NJ (M.
Saad, O. B. Garbuzenko, J. J. Khandare, Y.Wang, A. A. Vetcher, V. A. Soldatenkov, T.
Minko).
7. Toward in vivo targeted delivery of siRNA for efficient cancer therapy at The Annual
Retreat on Cancer Research in New Jersey,, May 28, 2008, Piscataway, NJ (O. Taratula,
R.Salva, I. Pandya, H. Geng, A. Wang, T. Minko, H. He).
8. Targeted nanocarier-based delivery of near-infrared cyanine dye enhances tumor imaging
in the Fourth Nanomedicine and Drug Delivery Symposium, October 10, 2006, Omaha, NE
(M. Saad, J. J. Khandare, Y. Wang, T. Minko).
9. JNK1 as a molecular target to decrease cellular mortality under hypoxia, 25th Annual
Meeting of the Graduate Research Association of Students in Pharmacy (GRASP), June 10-
12, 2005, New York, NY (S. Betigeri, R. I. Pakunlu, T. Minko).
10. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression
of multidrug resistance and antiapoptotic cellular defense: Novel multicomponent delivery
system, 24th Annual Meeting of the Graduate Research Association of Students in
Pharmacy (GRASP), June 4-6, 2004, Atlanta, GA (R. I. Pakunlu, Y. Wang, T. Minko).
11. Potential use of the combined liposomal hypoxia inducible factor 1 alpha antisense
oligonucleotides and doxorubicin as a novel anticancer therapy, 24th Annual Meeting of the
Graduate Research Association of Students in Pharmacy (GRASP), June 4-6, 2004, Atlanta,
GA (Y. Wang, R. I. Pakunlu, T. Minko).
12. Molecular targeting of drug delivery systems to cancer cells by BH3 and LHRH peptides,
23rd Annual Meeting of the Graduate Research Association of Students in Pharmacy
(GRASP), May 30 - June 1, 2003, Richmond, VA (S. S. Dharap, B. Qiu, S. Stein, P. J. Sinko,
T. Minko).
Poster Presentations of the Graduate Students, Postdoctoral Fellows and Researchers from
Minko s Lab Since 2000 (85)
1. Pulmonary co-delivery of anticancer drug and therapeutic antisense oligonucleotides by
mesoporous silica nanoparticles, Annual Meeting of the American Association of
Pharmaceutical Scientists, November 8-12, 2009, Los Angeles, CA (O. Taratula, O.
Garbuzenko, Z. Wang, G. Mainelis, T. Minko).
2. Inhalatory vs. Intravenous Co-Delivery of Anticancer Drugs and Antisense
Oligonucleotides/siRNA for Lung Cancer Treatment, Annual Meeting of the American
20
Tamara Minko
Association of Pharmaceutical Scientists, November 8-12, 2009, Los A
Contact this candidate